Catherine Kevane, a partner at Fenwick & West, on July 2 entered an appearance for Gritstone bio Inc. in a pending securities class action.
A complaint filed on June 17 by Pomerantz in the California Northern District Court alleged that Gritstone bio, which develops vaccines and immunotherapies for cancer and infectious diseases, misled investors about the timeline of a proposed COVID-19 vaccine study in earnings calls, news releases and U.S. Securities and Exchange Commission filings. The case was assigned to Judge Charles Breyer.
